Immunomedics starts Phase III

IMMU said it is beginning a Phase III trial of its LymphoCide epratuzumab humanized anti- CD22 monoclonal antibody to treat low-grade non-Hodgkin's lymphoma (NHL) in patients who had failed or are ref...